about
Type IIA topoisomerase inhibition by a new class of antibacterial agentsStructural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistanceEthionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitorsStructural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligandsDiscovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesisExpression, purification, characterization, and solution nuclear magnetic resonance study of highly deuterated yeast cytochrome C peroxidase with enhanced solubilityHigh-resolution structure of a papaya plant-defense barwin-like protein solved by in-house sulfur-SAD phasingProbing the N-terminal β-sheet conversion in the crystal structure of the human prion protein bound to a nanobodyLigand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approachesStructural relationships in the lysozyme superfamily: significant evidence for glycoside hydrolase signature motifs.Characterization of the PAS domain in the sensor-kinase BvgS: mechanical role in signal transmissionA general protocol for the generation of Nanobodies for structural biologyCrystallization and preliminary X-ray diffraction analysis of the peptidylprolyl isomerase Par27 of Bordetella pertussisRecombinant human prion protein inhibits prion propagation in vitro.Quiescin-sulfhydryl oxidase inhibits prion formation in vitro.Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.Biphenyl 2,3',4,5',6-pentakisphosphate, a novel inositol polyphosphate surrogate, modulates Ca2+ responses in rat hepatocytes.Structural analysis of the interaction between spiroisoxazoline SMARt-420 and the Mycobacterium tuberculosis repressor EthR2.Crystallization and initial crystallographic analysis of covalent DNA-cleavage complexes of Staphyloccocus aureus DNA gyrase with QPT-1, moxifloxacin and etoposide.Crystallization and preliminary X-ray diffraction analysis of a specific VHH domain against mouse prion protein.A novel expression system for production of soluble prion proteins in E. coli.Soluble polymorphic bank vole prion proteins induced by co-expression of quiescin sulfhydryl oxidase in E. coli and their aggregation behaviorsThe mannose-specific lectin domains of Flo1p from Saccharomyces cerevisiae and Lg-Flo1p from S. pastorianus: crystallization and preliminary X-ray diffraction analysis of the adhesin-carbohydrate complexes.Crystallization and preliminary X-ray diffraction analysis of kanamycin-binding β-lactamase in complex with its ligandProduction, crystallization and preliminary X-ray diffraction of the Gαs α-helical domain in complex with a nanobody.The Mycobacterium tuberculosis transcriptional repressor EthR is negatively regulated by Serine/Threonine phosphorylation.Structure and plasticity of the peptidyl-prolyl isomerase Par27 of Bordetella pertussis revealed by X-ray diffraction and small-angle X-ray scattering.Purification of ArcR, an oxidation-sensitive regulatory protein from Bacillus licheniformis.[Multiple post-translational modifications implied in the gene expression regulation: example of the sumoylation of Ets factors]Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.Expression and purification in high yield of a functionally active recombinant human Type I inositol(1,4,5)P3 5-phosphatase.Combining in-situ proteolysis and microseed matrix screening to promote crystallization of PrPc-nanobody complexesCorrection to Discovery, Structure–Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin InhibitorsThe Peptidyl–Prolyl Isomerase and Chaperone Par27 of Bordetella pertussis as the Prototype for a New Group of ParvulinsAn improved yeast surface display platform for the screening of nanobody immune librariesA fragment-based approach towards the discovery of N-substituted tropinones as inhibitors of Mycobacterium tuberculosis transcriptional regulator EthR2
P50
Q27663884-F55F47E7-8C9C-4A13-BCD7-C2E780718E46Q27664216-358950E3-271E-4918-8C3F-E07FE66A3CB6Q27675647-30CC52C3-1BDC-449B-817B-97EA810EB37AQ27676092-130D437C-E4BE-4725-A235-B85166A87155Q27681412-2093FAC2-3FBC-4338-84A4-D05671B9A526Q27684217-2BC43871-B9B1-463F-8830-43F30708B65BQ27686989-A65B4C49-D6A0-4DE2-A482-6C4802411F47Q27688102-07213AE3-DDAC-4BAD-A864-61CEE08CFABEQ27690213-7F1DE4B7-1802-462A-AF98-6EF974130A29Q33750272-C462736B-9EBC-4B1E-95DC-087AE1AA5FB3Q34863387-FE30AA2F-7697-41C7-BC1A-E346D71B5AAAQ34979957-386F785F-7626-49B8-A17F-61558D03B783Q36865962-FDDB8716-6D58-4567-93DB-802B10C97B49Q37221670-416C1E31-45B2-4EDC-97F1-40D58810338DQ37610204-69B99E7F-38A8-4761-AA57-C9A206E62B17Q38912109-0FB50077-6518-4DC3-9CFD-481498BF05AFQ40177242-7B505CB1-DA74-41A4-82ED-E07265E02EF8Q40248192-73DA9145-15C3-4A67-85E7-71D3C706E332Q40442144-47191F42-AC93-4A8D-BEA9-CF017774693BQ41162997-C88A59BD-6868-4C81-A68B-8D2F1AA8DED3Q41363533-3B56D3FA-BDDD-48CB-9721-B804E3F78412Q41924334-34E20602-9543-42DF-9A70-46EA43C50876Q42004421-B5519C2E-9A8F-46DB-97D9-F28147FD8437Q42242343-C16DC4A3-C6E8-41DE-9F8E-AD89E282D915Q43005912-C1632FBB-3B0E-404B-BBA0-F62CEB8E541EQ43898700-3D21448E-23F9-4C02-B9E4-E891973B872CQ44138193-8EA388A8-9DB2-40F2-B6A1-7F7236FE3A2FQ45007272-F74F8659-D984-4B0A-B033-F32DFD1CF930Q46650352-EEDC21DC-681A-4C83-9022-B6F5C9CA9A6CQ48366011-C4159DF3-65BB-4C95-A8B0-6F37634D5009Q54440539-12EE193D-A8B3-4500-8832-BD14F7F715B1Q57267823-3715148C-2080-4734-B846-F042DED4C4AAQ57842696-66473101-E80D-46F7-A03C-2714068223B6Q58428546-F59C30FF-3BC0-426C-B4D8-9F12E6796DA7Q61445154-672E0D7D-1FF1-4A65-92FE-0DD43AD760A8Q91740200-77FB7249-4FE7-4B65-888F-0AC8B4C937E5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alexandre Wohlkonig
@ast
Alexandre Wohlkonig
@es
Alexandre Wohlkonig
@nl
Alexandre Wohlkönig
@de
Alexandre Wohlkönig
@en
type
label
Alexandre Wohlkonig
@ast
Alexandre Wohlkonig
@es
Alexandre Wohlkonig
@nl
Alexandre Wohlkönig
@de
Alexandre Wohlkönig
@en
altLabel
A Wohlkonig
@en
A Wohlkönig
@en
A. Wohlkonig
@en
A. Wohlkönig
@en
Alexandre Wohlkonig
@en
Wohlkonig A
@en
Wohlkonig A.
@en
Wohlkonig
@en
Wohlkönig A
@en
Wohlkönig A.
@en
prefLabel
Alexandre Wohlkonig
@ast
Alexandre Wohlkonig
@es
Alexandre Wohlkonig
@nl
Alexandre Wohlkönig
@de
Alexandre Wohlkönig
@en
P106
P31
P496
0000-0003-3103-5022